This week's biopharma funding and startup activity, including a number of new companies launching. Santa Ana Bio, headquartered in Alameda, California, is advancing its pipeline of biologics targeting autoimmune and inflammatory diseases. Meanwhile, Adcytherix, based in Marseille, France, is developing novel antibody-drug conjugate (ADC) therapies.
Want to get this list of recently funded companies and more data? Fill out a quote request to get more info (Quote Request Form)
FIG. 1. Recent Biotech Funding Activity.
– Private Funding –
Santa Ana Bio
💸 Launched with $168 million in funding from combined Series A and B rounds to advance its precision immunology pipeline. The lead asset is SAB03, targeting autoimmune and inflammatory diseases, clinical trials are planned for 2025.
Amber Therapeutics
💸 Closed $100M Series A funding led by New Enterprise Associates (NEA) to advance Amber-UI for Mixed Urinary Incontinence (MUI) through pilot and pivotal studies toward regulatory approval in the US.
Alzheon, Inc
💸 Raised $100M in Series E round led by Alerce Medical Technology Partners to fund the completion of its Ph 3 study for lead candidate (ALZ-801) for Alzheimer's disease (AD) later this year.
Adcytherix
💸 Launched with €30M in seed funding led by Pontifax to develop next-generation novel ADCs for the treatment of different diseases such as cancer.
Moleculent
💸 Launched with $26M Series A financing led by ARCH Venture Partners to study cell-to-cell interaction.
– Post-IPO/Public Funding –
Avidity Biosciences
🏦 Announced pricing of $400.9M public offering.
Ultragenyx Pharmaceutical Inc.
🏦 Announced pricing of $350M public offering.
Abeona Therapeutics
🏦 Filed for $300M securities offering to fund BLA resubmission and pz-cel commercialization.
Disc Medicine Inc
🏦 Announced $178M public offering.
Replimune Group Inc
🏦 Announced $100M private placement financing to support a potential launch of RP1.
---
Article History:
RF, DV, DG (06/18/24)
This article is not investment or legal advice.
Comments